Thus, FBN1 may indirectly suppress the expressions of E-cadherin, beta-catenin, and induce the expressions of MMPs through the TGF-beta-mediated signaling, although it is possible that FBN1 may function as a secretive matrix protein to interact with membrane receptors, which thereby activates additional signal pathways to regulate EMT and the expressions of these proteins in ovarian cancer cells. The gene discussed is CTNNB1; the disease is ovarian carcinoma.